Thymosin Alpha-1 and Thymalin are both thymic peptides studied for immune modulation, but they differ in definition and evidence. Thymosin Alpha-1 is a single, well-defined peptide approved in a number of countries (as Zadaxin); Thymalin is a thymic peptide preparation associated mainly with Russian research. Neither is FDA-approved in the US.
At a glance
| Thymosin Alpha-1 | Thymalin | |
|---|---|---|
| Type | Single defined peptide | Thymic peptide preparation |
| Brand name | Zadaxin (outside US) | None (research/clinical, Russia) |
| FDA status | Not approved in US | Not approved in US |
| Approved elsewhere | Yes — multiple countries (e.g. hepatitis) | Used clinically in Russia |
| Studied for | T-cell function, infections, immune support | Immune modulation |
| Evidence | Defined trials in approved settings | Largely from originating research groups |
The bottom line
Bottom line: Thymosin Alpha-1 is the better-defined, more widely-studied option — a single peptide approved in several countries for specific conditions, though not in the US. Thymalin is a thymic preparation with mostly Russian-origin evidence and less independent replication. Neither is FDA-approved domestically.
Frequently asked questions
What's the difference between thymosin alpha-1 and thymalin?
Thymosin alpha-1 is a single, well-defined peptide approved in several countries (as Zadaxin), while thymalin is a thymic peptide preparation used mainly in Russian clinical practice. Neither is FDA-approved in the US.
Is thymosin alpha-1 FDA-approved?
It is approved in a number of countries (as Zadaxin) for conditions like hepatitis, but it is not FDA-approved in the United States. Thymalin is also not FDA-approved.
Do thymic peptides boost immunity?
Thymic peptides like these modulate T-cell function and are used clinically in some countries, but independent evidence varies and most are not FDA-approved. Claims should be weighed against the strength of the evidence.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Naylor PH, Quadrini K, Garaci E, Rasi G, Hadden JW. Immunopharmacology of thymosin alpha-1 and cytokine synergy. Ann N Y Acad Sci. 2007. Peer-reviewed study
- Dominari A, Hathaway D III, Pandav K, et al. Thymosin alpha-1: A comprehensive review of the literature. World J Virol. 2020. Peer-reviewed study
- Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019. Peer-reviewed study
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001. Peer-reviewed study
- Simonova MA, Ivanov I, Shoshina NS, et al. Aging and Thymosin Alpha-1. Int J Mol Sci. 2025. Peer-reviewed study
- Pei F, Guan X, Wu J. Thymosin alpha 1 treatment for patients with sepsis. Expert Opin Biol Ther. 2018. Peer-reviewed study
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003. Peer-reviewed study
- Khavinson VKh, Morozov VG. Geroprotective effect of thymalin and epithalamin. Adv Gerontol. 2002. Peer-reviewed study
- Khavinson VK, Linkova NS, Kvetnoy IM, et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020. Peer-reviewed study
- Linkova N, Khavinson V, Diatlova A, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. 2023. Peer-reviewed study
- Boiko AA, Malanchuk VA, Myroshnychenko MS. Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study. Wiad Lek. 2024. Peer-reviewed study
- Zhukova GV, Schikhlyarova AI, Barteneva TA, et al. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bull Exp Biol Med. 2018. Peer-reviewed study